Roche Holding AG Virtual Event on Key Evrysdi Data Presented at 2021 CureSMA Annual Meeting Transcript
This meeting is being recorded. (Operator Instructions) At this time, it's my pleasure to introduce Karl Mahler, Head of Investor Relations and Group Planning. Karl, the stage is yours.
Yes. Thanks a lot, Henrik. Welcome, everybody, to our fifth science call this year. We have 1 hour reserved for you, half an hour for presentation and half an hour for the Q&A. And of course, I mean if you find difficulties or have difficulties to enter into the Zoom system, which I don't assume now, but you can also, of course, drop an e-mail directly to [email protected].
So I'm joined today by Kathryn Wagner. She is the Vice President of Neuromuscular Disorders, Clinical Development with Roche. Many of you may know her from her previous jobs and engagement. She was a Director of the Center of Genetic Muscle Disorders of the Kennedy Krieger Institute. She was Professor at the Johns Hopkins University, and she is well-known for her initiatives in the whole CNS field, but in particular, on the Duchenne disease research.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
